Akero Therapeutics Stock Today
| AKRO Stock | USD 50.52 1.29 2.62% |
PerformanceOK
| Odds Of DistressLow
|
Akero Therapeutics is selling at 50.52 as of the 16th of February 2025; that is 2.62 percent increase since the beginning of the trading day. The stock's open price was 49.23. Akero Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of June 2019 | Category Healthcare | Classification Health Care |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. The company has 76.23 M outstanding shares of which 3.63 M shares are presently shorted by private and institutional investors with about 1.76 trading days to cover. More on Akero Therapeutics
Moving together with Akero Stock
Moving against Akero Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Akero Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Andrew MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAkero Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Akero Therapeutics' financial leverage. It provides some insight into what part of Akero Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Akero Therapeutics (AKRO) is traded on NASDAQ Exchange in USA. It is located in 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 60 people. Akero Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.85 B. Akero Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 76.23 M outstanding shares of which 3.63 M shares are presently shorted by private and institutional investors with about 1.76 trading days to cover.
Akero Therapeutics currently holds about 180.72 M in cash with (145.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81.
Check Akero Therapeutics Probability Of Bankruptcy
Ownership AllocationAkero Therapeutics holds a total of 76.23 Million outstanding shares. The majority of Akero Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Akero Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Akero Therapeutics. Please pay attention to any change in the institutional holdings of Akero Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Akero Ownership Details
Akero Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Boxer Capital Llc | 2024-09-30 | 1.7 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.6 M | |
| Redmile Group, Llc | 2024-09-30 | 1.4 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 1.3 M | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 1.1 M | |
| Jpmorgan Chase & Co | 2024-09-30 | 976.1 K | |
| Rock Springs Capital Management Lp | 2024-09-30 | 933.4 K | |
| Logos Global Management Lp | 2024-09-30 | 800 K | |
| Wellington Management Company Llp | 2024-09-30 | 7.9 M | |
| Hhg Plc | 2024-09-30 | 7.1 M |
Akero Therapeutics Historical Income Statement
Akero Stock Against Markets
Akero Therapeutics Corporate Management
| Timothy Rolph | CoFounder Officer | Profile | |
| Patrick Lamy | Senior Strategy | Profile | |
| Scott Gangloff | Chief Officer | Profile | |
| Catriona Yale | Executive Officer | Profile | |
| Thomas Ross | Senior Legal | Profile | |
| William JD | CFO, VP | Profile |
Already Invested in Akero Therapeutics?
The danger of trading Akero Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akero Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akero Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akero Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.